about
Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probeSolubility improvement of an anthrax toxin peptide inhibitor by rational amino acid randomization.Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogensA novel phage-library-selected peptide inhibits human TNF-α binding to its receptors.Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer.Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drugIn vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate.Immunomodulatory and Anti-inflammatory Activity in Vitro and in Vivo of a Novel Antimicrobial Candidate.Models of In-Vivo Bacterial Infections for the Development of Antimicrobial Peptide-based Drugs.Nanoparticles exposing neurotensin tumor-specific drivers.Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions.Oxidative stress-induced apoptosis in peripheral blood lymphocytes from patients with POLG-related disorders.Investigations into the killing activity of an antimicrobial peptide active against extensively antibiotic-resistant K. pneumon iae and P. aeruginosa.Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo.Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene.The proteome speciation of an immortalized cystic fibrosis cell line: New perspectives on the pathophysiology of the disease.Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents.A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo.Coupling to a cancer-selective heparan-sulfate-targeted branched peptide can by-pass breast cancer cell resistance to methotrexate.Near-infrared quantum dots labelled with a tumor selective tetrabranched peptide for in vivo imaging.Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return.Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells.Synthesis and biological activity of stable branched neurotensin peptides for tumor targetingTarget-selective drug delivery through liposomes labeled with oligobranched neurotensin peptidesSite-specific pegylation of an antimicrobial peptide increases resistance to Pseudomonas aeruginosa elastaseAntimicrobial Peptide-Loaded Nanoparticles as Inhalation Therapy for Pseudomonas aeruginosa InfectionsA New NT4 Peptide-Based Drug Delivery System for Cancer TreatmentUnraveling Heparan Sulfate Proteoglycan Binding Motif for Cancer Cell SelectivityNMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial PeptideAn antimicrobial molecule mitigates signs of sepsis in vivo and eradicates infections from lung tissueMolecular definition of the interaction between a tumor-specific tetrabranched peptide and LRP6 receptor
P50
Q27347532-9648FFB2-C6CB-421C-84D3-C559863DB6CAQ33357664-3BD0EB5B-8ABF-41FD-94F3-D8ACC7E0DBEAQ34441271-C0C51C3F-201F-449D-8BC5-2ACE7F4AAE40Q35181384-49073865-7246-4F51-B4FE-F75551D53D2CQ35578796-56E98328-170D-40D8-B644-2B2C556FB908Q36340055-E8620D89-5E6C-4AD1-B855-E9057FF4F2B2Q36893415-AA6CDD1E-EF1D-4C51-93E5-89F85810208CQ37551534-B79D5045-2F38-4DF0-9C1E-291B03522EF6Q38895330-4DBEE64D-47B1-45CE-AD05-47CBB8B8298FQ39189330-A2992005-5EBA-4B22-B35A-1AA84F94C2C3Q39460911-C0440959-7520-4D52-913D-9792A8B04498Q39476639-3CDEEEAF-0C03-4C1D-8E27-EE2A6EFF8978Q40184373-B28FED15-792D-4BC3-BD5C-16018DCA2AEDQ40340725-F9B8F680-8606-4214-B45E-A825967C7AAAQ42071455-F4C9BF1C-2B01-4F39-B83C-F8C500DD6F0DQ42474567-923AF48C-A9EA-4B58-BBB1-6E6AC598B8F6Q42694535-98832C66-B6B7-4C3A-A398-FB93EF86B6F9Q43133919-8FD092FA-22D0-4A26-9E31-F18F33199DCAQ43241056-B97294AD-9A96-4EBA-B554-6F360A47056EQ47128720-08AE1064-9A3F-41CE-BC73-B9DD0C3B2BE4Q52676096-2FF1EE86-770C-4B36-AD23-FE99E88B1768Q53113265-F1D6F8F1-02E6-49C9-A12D-7732954BA644Q54246454-ACB1A7DE-1AF6-4B7F-9F12-DE7A3BDA4B3EQ55318767-B9DB8359-7B8A-4439-BA24-5D24E82666F1Q80981625-B618F9C3-CEC6-48D3-B2CA-2BEAC70714EBQ83521129-975D561E-3DDF-4849-88F6-09FC0BA58AF8Q87258688-BB9FCC9F-A05A-44AD-8D7A-AAB556BC1024Q89939238-97EB8C1A-1DD0-45DE-9D21-261C291A029FQ89976540-B5A19B23-004E-4454-8844-EB6E1EDC3883Q90758145-2A4F5416-F58C-4279-9EFE-B6E0446D77F4Q91491139-B964C9F9-4E58-4D26-B18C-26602BBC0400Q92499443-E026EECB-4B6F-4F17-86FB-E4723FA88C53Q96581501-2E3DF200-5A58-401B-9AB9-E14DEA80B3CA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jlenia Brunetti
@ast
Jlenia Brunetti
@en
Jlenia Brunetti
@es
Jlenia Brunetti
@nl
Jlenia Brunetti
@sl
type
label
Jlenia Brunetti
@ast
Jlenia Brunetti
@en
Jlenia Brunetti
@es
Jlenia Brunetti
@nl
Jlenia Brunetti
@sl
prefLabel
Jlenia Brunetti
@ast
Jlenia Brunetti
@en
Jlenia Brunetti
@es
Jlenia Brunetti
@nl
Jlenia Brunetti
@sl
P214
P106
P1153
24467419400
P214
P31
P396
IT\ICCU\CFIV\269550
P496
0000-0001-8144-7186
P569
1982-01-01T00:00:00Z
P734
P7859
viaf-307342686